• English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • Deutsch 
    • English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • Einloggen
Dokumentanzeige 
  •   DSpace Startseite
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • Dokumentanzeige
  •   DSpace Startseite
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • Dokumentanzeige
JavaScript is disabled for your browser. Some features of this site may not work without it.
Gesamter Bestand
  • Bereiche & Sammlungen
  • Erscheinungsdatum
  • Autoren
  • Titeln
  • Schlagworten

Contemporary Management of Lower Urinary Tract Disease With Botulinum Toxin A: A Systematic Review of Botox (OnabotulinumtoxinA) and Dysport (AbobotulinumtoxinA)

Thumbnail
Autor
Mangera, A.; Andersson, K. E.; Apostolidis, A.; Chapple, C.; Dasgupta, P.; Giannantoni, A.; Gravas, S.; Madersbacher, S.
Datum
2011
DOI
10.1016/j.eururo.2011.07.001
Schlagwort
AbobotulinumtoxinA
Bladder outflow obstruction
Botox
Botulinum toxin
Detrusor sphincter dyssynergia
Dysport
Idiopathic detrusor
overactivity
Neurogenic detrusor overactivity
OnabotulinumtoxinA
Painful bladder syndrome
NEUROGENIC DETRUSOR OVERACTIVITY
BENIGN PROSTATIC HYPERPLASIA
NEUROTOXIN TYPE-A
QUALITY-OF-LIFE
CYSTITIS/PAINFUL BLADDER SYNDROME
MULTIPLE-SCLEROSIS PATIENTS
PLACEBO-CONTROLLED TRIAL
SPINAL-CORD
DISEASE
SPHINCTER DYSSYNERGIA
DOUBLE-BLIND
Urology & Nephrology
Zur Langanzeige
Zusammenfassung
Context: The use of botulinum toxin A (BoNTA) in the treatment of lower urinary tract dysfunction has expanded in recent years and the off-licence usage list includes neurogenic detrusor overactivity (NDO), idiopathic detrusor overactivity (IDO), painful bladder syndrome (PBS), and lower urinary tract symptoms resulting from bladder outflow obstruction (BOO) or detrusor sphincter dyssynergia (DSD). There are two commonly used preparations of BoNTA: Botox (onabotulinumtoxinA) and Dysport (abobotulinumtoxinA). Objective: To compare the reported outcomes of onabotulinumtoxinA and abobotulinumtoxinA in the treatment of NDO, IDO, PBS, DSD, and BOO for adults and children. Evidence acquisition: We performed a systematic review of the published literature on PubMed, Scopus, and Embase in the English language reporting on outcomes of both BoNTA preparations. Review articles and series with < 10 cases were excluded. The articles were graded for level of evidence and conclusions drawn separately for data with higher-level evidence. Evidence synthesis: There is high-level evidence for the use of onabotulinumtoxinA and abobotulinumtoxinA in adults with NDO but only for abobotulinumtoxinA in children with NDO. Only onabotulinumtoxinA has level 1 evidence supporting its use in IDO, BOO, DSD, and PBS/interstitial cystitis. Conclusions: We identified good-quality studies that evaluated onabotulinumtoxinA for all the indications described above in adults; such was not the case with abobotulinumtoxinA. Although this does not imply that onabotulinumtoxinA is more effective than abobotulinumtoxinA, it should be a consideration when counselling patients on the use of botulinum toxin in urologic applications. The two preparations should not be used interchangeably, either in terms of predicting outcome or in determining doses to be used. (C) 2011 European Association of Urology. Published by Elsevier B. V. All rights reserved.
URI
http://hdl.handle.net/11615/30613
Collections
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ. [19735]
htmlmap 

 

Stöbern

Gesamter BestandBereiche & SammlungenErscheinungsdatumAutorenTitelnSchlagwortenDiese SammlungErscheinungsdatumAutorenTitelnSchlagworten

Mein Benutzerkonto

EinloggenRegistrieren
Help Contact
DepositionAboutHelpKontakt
Choose LanguageGesamter Bestand
EnglishΕλληνικά
htmlmap